Inhaled Furosemide for Transient Tachypnea of Newborn
Not Applicable
Completed
- Conditions
- Respiratory Morbidity
- Registration Number
- NCT04397991
- Lead Sponsor
- Makassed General Hospital
- Brief Summary
This is a randomized double blind clinical trial in which newborns with suspected Transient tachypnea of the newborn (TTN) will receive either furosemide or normal saline by nebulizer every 6 hours for 24 hours.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
- Neonates with 34+0-39+0 gestational age
- on the first day of life
- with the clinical diagnosis of Transient Tachypnoea
- need for CPAP >6 hours to obtain the oxygen saturation >92%
Exclusion Criteria
- Systemic infection
- Intubation and mechanical ventilation before Inclusion in the trail
- Malformation and any other disease with disturb of respiratory system
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Percentage of patients with respiratory morbidity 24 hours Neonatal respiratory morbidity will be assessed through oxygen saturation, respiratory rate and duration on Continuous positive airway pressure (CPAP)
- Secondary Outcome Measures
Name Time Method Length of hospital stay 15 days Duration of hospital stay in days
Trial Locations
- Locations (1)
Makassed General Hospital
🇱🇧Beirut, Lebanon
Makassed General Hospital🇱🇧Beirut, Lebanon